Independent Review Committee

What an International Sustainability Standards Board means for Canada

Retrieved on: 
Tuesday, November 9, 2021
Josef Waitzer, Independent Review Committee, ISSB, Review, Thought, Sustainability, Centre for International Sustainable Development Law, ESG, Oil, Audit

TORONTO, Nov. 9, 2021 /CNW/ -The need for a Canadian Sustainability Standards Board is clearer than ever, says Edward J. Waitzer, Chair of the IndependentReview Committee on Standard Setting in Canada.

Key Points: 
  • TORONTO, Nov. 9, 2021 /CNW/ -The need for a Canadian Sustainability Standards Board is clearer than ever, says Edward J. Waitzer, Chair of the IndependentReview Committee on Standard Setting in Canada.
  • The need for a Canadian Sustainability Standards Board is clearer than ever.
  • "As a result, we think it is critical to establish a Canadian Sustainability Standards Board that works alongside Canada's existing accounting, auditing, and assurance standards bodies."
  • A Canadian Sustainability Standards Board will also liaise with the new ISSB, ensuring that the Canadian perspective is part of international decision making.

Ninepoint Partners LP Announces Wind-Up of Ninepoint Corporate Class Funds in 2021

Eastern Time Zone, NEO Exchange, Income Tax Act, Independent Review Committee, Intention, NEO, Mergers and acquisitions, GLOBE, Ninepoints, Pennsylvania, Section 50C of the Isle of Man Income Tax Act 1970, Real assets, Dollar for Dollar, Divergence (computer science), Corporation, Solution, Airline, Security (finance)

TORONTO, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Ninepoint Partners LP (Ninepoint Partners) announced today its intention to windup Ninepoint Corporate Class Inc. (the Corporation).

Key Points: 
  • TORONTO, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Ninepoint Partners LP (Ninepoint Partners) announced today its intention to windup Ninepoint Corporate Class Inc. (the Corporation).
  • Each of Ninepoint Diversified Bond Class, Ninepoint Resource Class, Ninepoint Silver Equities Class, Ninepoint Risk Advantaged U.S. Equity Index Class, Ninepoint Return Advantaged U.S. Equity Index Class and Ninepoint Focused Global Dividend Class (each, a Terminating Fund and collectively, the Terminating Funds) will be merged into its trust fund equivalent (each, a Continuing Fund and collectively, the Continuing Funds) which has, or will have, a substantially similar investment objective, investment portfolio, fee structure and valuation procedure and is, or will be, managed by the same portfolio management team (collectively, the Mergers).
  • Existing investors of the Terminating Funds as of October 1, 2021, will be mailed an investor notice today.
  • For more information on Ninepoint Partners, please visit www.ninepoint.com or please contact us at (416) 943-6707 or (866) 299-9906 or [email protected].

Oncopeptides presents phase 3 OCEAN study results at the IMW meeting

Retrieved on: 
Saturday, September 11, 2021

The data was presented today by Fredrik Schjesvold, Head of Oslo Myeloma Center, Norway, at the 18th International Myeloma Workshop (IMW) in Vienna.

Key Points: 
  • The data was presented today by Fredrik Schjesvold, Head of Oslo Myeloma Center, Norway, at the 18th International Myeloma Workshop (IMW) in Vienna.
  • This benefit of pomalidomide over melflufen in the ASCT subgroup has contributed to the HR of 1.1 in the ITT population.
  • "The oral presentation of OCEAN study results at the IMW meeting represents an important milestone for Oncopeptides", says Marty J Duvall, Chief Executive Officer at Oncopeptides.
  • "The efficacy and safety data from the OCEAN study provide new and important insights for the multiple myeloma society", says PieterSonneveld, MD, PhD, Professor of Hematology at theErasmusUniversity of Rotterdam, and Principal Investigator of the OCEAN study.

Oncopeptides presents phase 3 OCEAN study results at the IMW meeting

Retrieved on: 
Saturday, September 11, 2021

The data was presented today by Fredrik Schjesvold, Head of Oslo Myeloma Center, Norway, at the 18th International Myeloma Workshop (IMW) in Vienna.

Key Points: 
  • The data was presented today by Fredrik Schjesvold, Head of Oslo Myeloma Center, Norway, at the 18th International Myeloma Workshop (IMW) in Vienna.
  • This benefit of pomalidomide over melflufen in the ASCT subgroup has contributed to the HR of 1.1 in the ITT population.
  • "The oral presentation of OCEAN study results at the IMW meeting represents an important milestone for Oncopeptides", says Marty J Duvall, Chief Executive Officer at Oncopeptides.
  • "The efficacy and safety data from the OCEAN study provide new and important insights for the multiple myeloma society", says PieterSonneveld, MD, PhD, Professor of Hematology at theErasmusUniversity of Rotterdam, and Principal Investigator of the OCEAN study.

Oncopeptides presents new data from OCEAN and PORT study - abstracts online

Retrieved on: 
Friday, August 27, 2021
RRMM, Melphalan, PFS, Population, ITT, Hematologic disease, Lenalidomide, Capital, OS, OCEAN, Progression-free survival, Trial of the century, Corporate communication, INN, Independent Review Committee, PORT, Hazard ratio, Dexamethasone, Intention, Nasdaq, Disease, Doctor of Philosophy, Nasdaq Stockholm, Hospital, Aminopeptidase, Immunomodulatory imide drug, IMW, PDC, Safety, Adult, IRC, Patient, HR, FDA, CET, MD, Pharmaceutical industry

More comprehensive data will be presented at the IMW-meeting in Vienna on September 11, at 10:00 (CET).

Key Points: 
  • More comprehensive data will be presented at the IMW-meeting in Vienna on September 11, at 10:00 (CET).
  • The phase 3 OCEAN study is a head-to-head comparison evaluating the efficacy and safety of melflufen (INN melphalan flufenamide) plus dexamethasone versus pomalidomide plus dexamethasone.
  • At the IMW Oncopeptides will also present data from the phase 2 PORT study, an open-label, randomized, cross-over study which compares safety, tolerability and efficacy of peripheral or central intravenous administration of melflufen in combination with dexamethasone in patients with RRMM.
  • Melphalan flufenamide is evaluated in a comprehensive clinical study program including the global phase 3 studies OCEAN and LIGHTHOUSE.

Oncopeptides presents new data from OCEAN and PORT study - abstracts online

Retrieved on: 
Friday, August 27, 2021
RRMM, Melphalan, PFS, Population, ITT, Hematologic disease, Lenalidomide, Capital, OS, OCEAN, Progression-free survival, Trial of the century, Corporate communication, INN, Independent Review Committee, PORT, Hazard ratio, Dexamethasone, Intention, Nasdaq, Disease, Doctor of Philosophy, Nasdaq Stockholm, Hospital, Aminopeptidase, Immunomodulatory imide drug, IMW, PDC, Safety, Adult, IRC, Patient, HR, FDA, CET, MD, Pharmaceutical industry

More comprehensive data will be presented at the IMW-meeting in Vienna on September 11, at 10:00 (CET).

Key Points: 
  • More comprehensive data will be presented at the IMW-meeting in Vienna on September 11, at 10:00 (CET).
  • The phase 3 OCEAN study is a head-to-head comparison evaluating the efficacy and safety of melflufen (INN melphalan flufenamide) plus dexamethasone versus pomalidomide plus dexamethasone.
  • At the IMW Oncopeptides will also present data from the phase 2 PORT study, an open-label, randomized, cross-over study which compares safety, tolerability and efficacy of peripheral or central intravenous administration of melflufen in combination with dexamethasone in patients with RRMM.
  • Melphalan flufenamide is evaluated in a comprehensive clinical study program including the global phase 3 studies OCEAN and LIGHTHOUSE.

BMO Investments Inc. Announces New Mutual Fund Series

Retrieved on: 
Thursday, August 26, 2021
Independent Review Committee, Series A round, Divergence (computer science), Series, Effective date, Name, BMO Global Smaller Companies, SEDAR, Mergers and acquisitions, Animal, Life insurance, Mail, Security (finance), Financial adviser

BMOII also announced today a proposal to merge (the "Merger"), subject to obtaining all necessary securityholder and regulatory approvals, BMO Global Growth & Income Fund (the "Terminating Fund") into BMO Global Equity Fund (the "Continuing Fund").

Key Points: 
  • BMOII also announced today a proposal to merge (the "Merger"), subject to obtaining all necessary securityholder and regulatory approvals, BMO Global Growth & Income Fund (the "Terminating Fund") into BMO Global Equity Fund (the "Continuing Fund").
  • If securityholders of the Series F units of the Terminating Fund do not approve the Merger, the Manager proposes to terminate the Series F units of the Terminating Fund and redeem such units prior to the Effective Date.
  • Subject to obtaining all necessary approvals, including any approvals with respect to the ETF Series of BMO Global Multi-Sector Bond Fund, BMOII proposes to change the investment objectives for each of BMO Global Multi-Sector Bond Fundand BMO Global Balanced Fund, which will result in corresponding other changes to the funds, including:
    Changes to the investment strategies to reflect a responsible investment approach; and
    Changing the names of the funds to BMO Sustainable Global Multi-Sector Bond Fund and BMO Sustainable Global Balanced Fund, respectively.
  • The management fee applicable to Series A, Advisor Series and Series T6 securities of BMO Global Equity Fund will be reduced effective on or about November 19, 2021 to facilitate the Merger as follows:

NCM Asset Management Ltd. Announces Change to Its Investment Fund Line-Up

Retrieved on: 
Monday, August 16, 2021
Growth, The Meeting, Fund, Investment, Trust, Independent Review Committee, SEDAR, NCM, Reasonably Priced Comics, GARP, Income, Security (finance), Financial adviser, Lithium

Calgary, Alberta--(Newsfile Corp. - August 16, 2021) - NCM Asset Management Ltd. ("NCM"), the manager of a strategically focused group of public mutual funds, alternative investment funds, and related products and services, announced plans to change the investment objectives of NCM Core American.

Key Points: 
  • Calgary, Alberta--(Newsfile Corp. - August 16, 2021) - NCM Asset Management Ltd. ("NCM"), the manager of a strategically focused group of public mutual funds, alternative investment funds, and related products and services, announced plans to change the investment objectives of NCM Core American.
  • Subject to obtaining shareholder approval, NCM Core American will change its investment objectives as indicated below and be renamed NCM Core International.
  • The Independent Review Committee of the fund has reviewed the potential conflict of interest matters related to the proposed investment objectives change and provided NCM with a positive recommendation for the proposed investment objectives change after determining that the change, if implemented, would achieve a fair and reasonable result for the fund.
  • About NCM - NCM Asset Management Ltd.
    For over 20 years, NCM has been one of Canada's leaders in actively managed investment products.

Scotia Global Asset Management proposes changes to select ScotiaFunds

Retrieved on: 
Thursday, August 12, 2021
Prospectus, NYSE, Independent Review Committee, TSX, Notice, North America, Toronto Stock Exchange, Partnership, Investment, BNS, Mergers and acquisitions, ETF, New York Stock Exchange, Scotiabank, Solactive, Funding, GBS, Solution, Animal, Financial services, Life insurance, Security (finance), Online shopping

TORONTO, Aug. 12, 2021 /CNW/ - Scotia Global Asset Management (Scotia GAM) today announced proposed changes to select ScotiaFunds to streamline its lineup, create efficiencies and deliver incremental costs savings to clients.

Key Points: 
  • TORONTO, Aug. 12, 2021 /CNW/ - Scotia Global Asset Management (Scotia GAM) today announced proposed changes to select ScotiaFunds to streamline its lineup, create efficiencies and deliver incremental costs savings to clients.
  • Special meetings of select ScotiaFunds (each, a Special Meeting), will be held virtually on or about October 28, 2021, at which time applicable unitholders will be asked to consider and vote upon certain proposed changes, as detailed below.
  • Scotia Global Asset Management is a business name used by 1832 Asset Management L.P., a limited partnership, the general partner of which is wholly owned by Scotiabank.
  • Scotia Global Asset Management offers a range of wealth management solutions, including mutual funds,ETFs, and investment solutions for private clients, institutional clients and managed asset programs.

Update on OSC operations in response to COVID-19

Retrieved on: 
Tuesday, March 24, 2020
Economy, Finance, Money, Canadian Securities Administrators, Ontario Securities Commission, Canadian securities regulation, Security, Investor, Independent Review Committee

Under the order, workplaces engaged in capital markets activities are considered to provide essential services and can remain open.

Key Points: 
  • Under the order, workplaces engaged in capital markets activities are considered to provide essential services and can remain open.
  • As such, Ontario Securities Commission (OSC) staff continue to operate at the level necessary to deliver crucial services to the market and to protect Ontario investors.
  • The OSC, along with its Canadian Securities Administrators (CSA) partners, provided temporary blanket relief from certain regulatory filings on March 23, 2020.
  • Investors are urged to check the registration of any persons or company offering an investment opportunity and to review the OSC investor materials available at http://www.osc.gov.on.ca .